Changes in pain and insulin-like growth factor 1 in fibromyalgia during exercise: the involvement of cerebrospinal inflammatory factors and neuropeptides

Arthritis Research and Therapy

Volumn 14, Issue 4, 2012, Pages

  Bjersing, Jan L ^a,b   Dehlin, Mats ^a,b   Erlandsson, Malin ^a   Bokarewa, Maria I ^a,b   Mannerkorpi, Kaisa ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 8; NERVE GROWTH FACTOR; NEUROPEPTIDE; NEUROPEPTIDE Y; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; STROMELYSIN; SUBSTANCE P; AUTACOID; BIOLOGICAL MARKER;

ADULT; AEROBIC EXERCISE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; EXERCISE INTENSITY; FEMALE; FIBROMYALGIA; HUMAN; MALE; PAIN ASSESSMENT; PAIN THRESHOLD; VISUAL ANALOG SCALE; WALKING; BLOOD; EXERCISE; MIDDLE AGED; PAIN; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

BIOLOGICAL MARKERS; EXERCISE; FEMALE; FIBROMYALGIA; HUMANS; INFLAMMATION MEDIATORS; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; NEUROPEPTIDES; PAIN;

EID: 84863502282     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3902     Document Type: Article

References (54)

1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russell IJ, Sheon RP. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33:160-172. 10.1002/art.1780330203, 2306288.
2. Clauw DJ. Fibromyalgia: an overview. Am J Med 2009, 122(12 Suppl):S3-S13.
3. Busch A, Schachter C, Overend T, Peloso P, Barber K. Exercise for fibromyalgia: a systematic review. J Rheumatol 2008, 35:1130-1144.
4. Mannerkorpi K, Nordeman L, Cider T, Jonsson G. Does moderate-to-high aerobic exercise result in better improvement of body impairments and pain than low-intensive exercise in FM? A prospective randomised controlled trial. Arthritis Res Ther 2010, 12:R189. 10.1186/ar3159, 2991024, 20942911.
5. Bennett RM, Cook DM, Clark SR, Burckhardt CS, Campbell SM. Hypothalamic-pituitary-insulin-like growth factor-1 axis dysfunction in patients with fibromyalgia. J Rheumatol 1997, 24:1384-1389.
6. Cuatrecasas G, Gonzalez MJ, Alegre C, Sesmilo G, Fernandez-Solà J, Casanueva FF, Garcia-Fructuoso F, Poca-Dias V, Izquierdo JP, Puig-Domingo M. High prevalence of growth hormone deficiency in severe fibromyalgia syndromes. J Clin Endocrinol Metab 2010, 95:4331-4337. 10.1210/jc.2010-0061, 20631018.
7. Bennett RM. Adult growth hormone deficiency in patients with fibromyalgia. Curr Rheumatol Rep 2002, 4:306-312. 10.1007/s11926-002-0039-4, 12126582.
8. Ross RL, Jones KD, Bennett RM, Ward RL, Druker BJ, Wood LJ. Preliminary evidence of increased pain and elevated cytokines in fibromyalgia patients with defective growth hormone response to exercise. Open Immunol J 2010, 3:9-18. 2868257, 20467575.
9. Berg U, Bang P. Exercise and circulating insulin-like growth factor I. Horm Res 2004, 62(Suppl 1):50-58.
10. Jones KD, Deodhar AA, Burckhardt CS, Perrin NA, Hanson GC, Bennett RM. A combination of 6 months of treatment with pyridostigmine and triweekly exercise fails to improve insulin-like growth factor-I levels in fibromyalgia, despite improvement in the acute growth hormone response to exercise. J Rheumatol 2007, 34:1103-1111.
11. Giovengo SL, Russell IJ, Larson AA. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 1999, 26:1564-1569.
12. Cirulli F, Alleva E. The NGF saga: from animal models of psychosocial stress to stress-related psychopathology. Front Neuroendocrinol 2009, 30:379-395. 10.1016/j.yfrne.2009.05.002, 19442684.
13. Yamauchi K, Inoue G, Koshi T, Yamashita M, Ito T, Suzuki M, Eguchi Y, Orita S, Takaso M, Nakagawa K, Aoki Y, Ochiai N, Kishida S, Endo M, Yamashita T, Takahashi K, Ohtori S. Nerve growth factor of cultured medium extracted from human degenerative nucleus pulposus promotes sensory nerve growth and induces substance P in vitro. Spine 2009, 34:2263-2269. 10.1097/BRS.0b013e3181a5521d, 19934806.
14. Yang XD, Liu Z, Liu HX, Wang LH, Ma CH, Li ZZ. Regulatory effect of nerve growth factor on release of substance P in cultured dorsal root ganglion neurons of rat. Neurosci Bull 2007, 23:215-220. 10.1007/s12264-007-0032-z, 17687396.
15. Frossard N, Freund V, Advenier C. Nerve growth factor and its receptors in asthma and inflammation. Eur J Pharmacol 2004, 500:453-465. 10.1016/j.ejphar.2004.07.044, 15464052.
16. Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, Lopez Y, MacKillip F. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994, 37:1593-1601. 10.1002/art.1780371106, 7526868.
17. Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988, 32:21-26. 10.1016/0304-3959(88)90019-X, 2448729.
18. Liu Z, Welin M, Bragee B, Nyberg F. A high-recovery extraction procedure for quantitative analysis of substance P and opioid peptides in human cerebrospinal fluid. Peptides 2000, 21:853-860. 10.1016/S0196-9781(00)00219-9, 10959008.
19. Di Franco M, Iannuccelli C, Alessandri C, Paradiso M, Riccieri V, Libri F, Valesini G. Autonomic dysfunction and neuropeptide Y in fibromyalgia. Clin Exp Rheumatol 2009, 27(5 Suppl 56):S75-S78.
20. Anderberg UM, Liu Z, Berglund L, Nyberg F. Elevated plasma levels of neuropeptide Y in female fibromyalgia patients. Eur J Pain 1999, 3:19-30. 10.1016/S1090-3801(99)90185-4, 10700334.
21. Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO. Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide. Recent Pat CNS Drug Discov 2006, 1:315-324. 10.2174/157488906778773689, 18221213.
22. Xapelli S, Silva AP, Ferreira R, Malva JO. Neuropeptide Y can rescue neurons from cell death following the application of an excitotoxic insult with kainate in rat organotypic hippocampal slice cultures. Peptides 2007, 28:288-294. 10.1016/j.peptides.2006.09.031, 17212973.
23. Upadhya MA, Dandekar MP, Kokare DM, Singru PS, Subhedar NK. Involvement of neuropeptide Y in the acute, chronic and withdrawal responses of morphine in nociception in neuropathic rats: behavioral and neuroanatomical correlates. Neuropeptides 2009, 43:303-314. 10.1016/j.npep.2009.05.003, 19556004.
24. Intondi AB, Dahlgren MN, Eilers MA, Taylor BK. Intrathecal neuropeptide Y reduces behavioral and molecular markers of inflammatory or neuropathic pain. Pain 2008, 137:352-365. 10.1016/j.pain.2007.09.016, 2556181, 17976913.
25. Liu H, Liu Z, Xu X, Yang X, Wang H, Li Z. Nerve growth factor regulates galanin and neuropeptide Y expression in primary cultured superior cervical ganglion neurons. Pharmazie 2010, 65:219-223.
26. Dina OA, Green PG, Levine JD. Role of interleukin-6 in chronic muscle hyperalgesic priming. Neuroscience 2008, 152:521-525. 10.1016/j.neuroscience.2008.01.006, 2336107, 18280048.
27. Alexander GM, van Rijn MA, van Hilten JJ, Perreault MJ, Schwartzman RJ. Changes in cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS. Pain 2005, 116:213-219. 10.1016/j.pain.2005.04.013, 15964681.
28. Ohtori S, Suzuki M, Koshi T, Takaso M, Yamashita M, Inoue G, Yamauchi K, Orita S, Eguchi Y, Kuniyoshi K, Ochiai N, Kishida S, Nakamura J, Aoki Y, Ishikawa T, Arai G, Miyagi M, Kamoda H, Suzuki M, Toyone T, Takahashi K. Proinflammatory cytokines in the cerebrospinal fluid of patients with lumbar radiculopathy. Eur Spine J 2010, 20:942-946. 3099164, 20953967.
29. Uceyler N, Häuser W, Sommer C. Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskel Disord 2011, 12:245.
30. Sachs D, Cunha FQ, Poole S, Ferreira SH. Tumour necrosis factor-alpha, interleukin-1beta and interleukin-8 induce persistent mechanical nociceptor hypersensitivity. Pain 2002, 96:89-97. 10.1016/S0304-3959(01)00433-X, 11932065.
31. Kadetoff D, Lampa J, Westman M, Andersson M, Kosek E. Evidence of central inflammation in fibromyalgia-increased cerebrospinal fluid interleukin-8 levels. J Neuroimmunol 2012, 242:33-38. 10.1016/j.jneuroim.2011.10.013, 22126705.
32. Wang H, Buchner M, Moser MT, Daniel V, Schiltenwolf M. The role of IL-8 in patients with fibromyalgia: a prospective longitudinal study of 6 months. Clin J Pain 2009, 2:1-4.
33. Rullman E, Norrbom J, Strömberg A, Wågsäter D, Rundqvist H, Haas T, Gustafsson T. Endurance exercise activates matrix metalloproteinases in human skeletal muscle. J Appl Physiol 2009, 106:804-812. 10.1152/japplphysiol.90872.2008, 19131480.
34. Rosenberg GA. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 2009, 8:205-216. 10.1016/S1474-4422(09)70016-X, 19161911.
35. Wang XB, Bozdagi O, Nikitczuk JS, Zhai ZW, Zhou Q, Huntley GW. Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic spine enlargement and long-term potentiation coordinately. Proc Natl Acad Sci USA 2008, 105:19520-19525. 10.1073/pnas.0807248105, 2614793, 19047646.
36. Yong VW. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 2005, 6:931-944. 10.1038/nrn1807, 16288297.
37. Kosek E, Ekholm J, Nordemar R. A comparison of pressure pain thresholds in different tissues and body regions: long-term reliability of pressure algometry in healthy volunteers. Scand J Rehabil Med 1993, 25:117-124.
38. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991, 18:728-733.
39. Mannerkorpi K, Svantesson U, Carlsson J, Ekdahl C. Tests of functional limitations in fibromyalgia syndrome: a reliability study. Arthritis Care Res 1999, 12:193-199. 10.1002/1529-0131(199906)12:3<193::AID-ART6>3.0.CO;2-N, 10513509.
40. Gregory SM, Headley SA, Germain M, Flyvbjerg A, Frystyk J, Coughlin MA, Milch CM, Sullivan S, Nindl BC. Lack of circulating bioactive and immunoreactive IGF-I changes despite improved fitness in chronic kidney disease patients following 48 weeks of physical training. Growth Horm IGF Res 2011, 21:51-56. 10.1016/j.ghir.2010.12.005, 21251861.
41. Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, Rosén T, Lindstedt G, Lundberg PA, Bengtsson BA. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol 1994, 41:351-357.
42. Staud R, Robinson ME, Price DD. Isometric exercise has opposite effects on central pain mechanisms in fibromyalgia patients compared to normal controls. Pain 2005, 118:176-184. 10.1016/j.pain.2005.08.007, 16154700.
43. Jones KD, Bennett RM, Ward RL, Deodhar AA. Description of a half-day interprofessional fibromyalgia clinic with an evaluation of patient satisfaction. Am J Phys Med Rehabil 2011, 90:825-833. 10.1097/PHM.0b013e31821f6ed3, 21681062.
44. Ross RL, Jones KD, Bennett RM, Ward RL, Druker BJ, Wood LJ. Preliminary evidence of increased pain and elevated cytokines in fibromyalgia patients with defective growth hormone response to exercise. Open Immunol J 2010, 3:9-18. 2868257, 20467575.
45. Liu X, Sandkuhler J. Characterization of long-term potentiation of C-fiber-evoked potentials in spinal dorsal horn of adult rat: essential role of NK1 and NK2 receptors. J Neurophysiol 1997, 78:1973-1982.
46. Hopkins ME, Davis FC, Vantieghem MR, Whalen PJ, Bucci DJ. Differential effects of acute and regular physical exercise on cognition and affect. Neuroscience 2012, 215:59-68.
47. Carro E, Nunez A, Busiguina S, Torres-Aleman I. Circulating insulin-like growth factor I mediates effects of exercise on the brain. J Neurosci 2000, 20:2926-2933.
48. Morgado C, Silva L, Pereira-Terra P, Tavares I. Changes in serotonergic and noradrenergic descending pain pathways during painful diabetic neuropathy: the preventive action of IGF1. Neurobiol Dis 2011, 43:275-284. 10.1016/j.nbd.2011.04.001, 21515376.
49. Karatay S, Yildirim K, Melikoglu MA, Akcay F, Senel K. Effects of dynamic exercise on circulating IGF-1 and IGFBP-3 levels in patients with rheumatoid arthritis or ankylosing spondylitis. Clin Rheumatol 2007, 26:1635. 10.1007/s10067-007-0559-4, 17322964.
50. Cuatrecasas G, Alegre C, Fernandez-Sola J, Gonzalez MJ, Garcia-Fructuoso F, Poca-Dias V, Nadal A, Navarro F, Mera A, Lage M, Peino R, Casanueva F, Linan C, Sesmilo G, Coves MJ, Izquierdo JP, Alvarez I, Granados E, Puig-Domingo M. Growth hormone treatment for sustained pain reduction and improvement in quality of life in severe fibromyalgia. Pain 2012, 153:1382-1389. 10.1016/j.pain.2012.02.012, 22465047.
51. Rullman E, Rundqvist H, Wågsäter D, Fischer H, Eriksson P, Sundberg CJ, Jansson E, Gustafsson T. A single bout of exercise activates matrix metalloproteinase in human skeletal muscle. J Appl Physiol 2007, 102:2346-2351. 10.1152/japplphysiol.00822.2006, 17255365.
52. Gottschall PE, Deb S. Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons. Neuroimmunomodulation 1996, 3:69-75. 10.1159/000097229, 8945720.
53. Kim KS, Kim HY, Joe EH, Jou I. Matrix metalloproteinase-3 induction in rat brain astrocytes: focus on the role of two AP-1 elements. Biochem J 2008, 410:605-611. 10.1042/BJ20071207, 18072934.
54. Kim YS, Kim SS, Cho JJ, Choi DH, Hwang O, Shin DH, Chun HS, Beal MF, Joh TH. Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. J Neurosci 2005, 25:3701-3711. 10.1523/JNEUROSCI.4346-04.2005, 15814801.